Antibiotics: Recarbrio gets FDA approval for treatment of HABP/VABP
by Press Release from Outbreak News Today on (#54D8H)
Merck announced Friday that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for RECARBRIOTM (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia [...]
The post Antibiotics: Recarbrio gets FDA approval for treatment of HABP/VABP appeared first on Outbreak News Today.